GeneDx (NASDAQ:WGS) Trading Up 7.9% on Analyst Upgrade

GeneDx Holdings Corp. (NASDAQ:WGS) traded up 7.9% during mid-day trading on Tuesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating. The company traded as high as $62.70 and last traded at $65.3090. 220,150 shares were traded during trading, a decline of 78% from the average daily volume of 992,343 shares. The stock had previously closed at $60.54.

A number of other brokerages also recently commented on WGS. BTIG Research reduced their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 target price on shares of GeneDx in a research report on Tuesday, May 5th. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Guggenheim reissued a “buy” rating and set a $74.00 price target (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $87.43.

Insider Activity at GeneDx

In other news, Director Casdin Capital, Llc bought 185,000 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the transaction, the director owned 3,367,164 shares in the company, valued at $143,441,186.40. The trade was a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Keith A. Meister purchased 533,758 shares of the stock in a transaction dated Thursday, May 7th. The stock was purchased at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is currently owned by company insiders.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Zacks upgraded GeneDx from “strong sell” to “hold,” signaling that the research firm sees less downside risk than previously. The change may provide limited support for WGS, but it is not a bullish recommendation. Zacks.com
• Neutral Sentiment: Multiple law firms reminded investors that August 3, 2026 is the deadline to seek appointment as lead plaintiff in the pending securities class action. The notices apply to investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026. The deadline is procedural and does not establish that GeneDx committed wrongdoing. Rosen Law Firm deadline notice
• Negative Sentiment: The litigation creates downside risk for GeneDx and WGS shareholders. Investor complaints allege that the company and certain officers misrepresented the performance and benefits of an acquisition, including a promised $51 million contribution that was followed by a reported $31.2 million write-off within 12 months. Other allegations focus on deteriorating reimbursement rates and margin compression that were allegedly not disclosed. The reported events contributed to a sharp stock decline and could expose GeneDx to litigation costs, damages, and reputational harm, though the allegations remain unproven. SueWallSt GeneDx lawsuit notice

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently modified their holdings of WGS. Goldman Sachs Group Inc. lifted its holdings in GeneDx by 4.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after acquiring an additional 52,322 shares during the last quarter. Vanguard Group Inc. raised its position in shares of GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after purchasing an additional 18,647 shares during the period. Franklin Resources Inc. raised its position in shares of GeneDx by 60.4% during the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

GeneDx Stock Up 2.8%

The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -24.47 and a beta of 1.90. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average of $59.88 and a 200-day moving average of $70.44.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the previous year, the company earned ($0.23) earnings per share. As a group, sell-side analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.